Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

EURONANOMED: Búsqueda de pyme en el campo de cardiología que trabaje en biomedicina y biosensores

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDES20161201001
Publicado:
11/01/2017
Caducidad:
22/12/2017
Resumen:
Un consorcio internacional formado por grupos de investigación en nanotecnología, materiales, biomedicina y cardiología busca un socio industrial con el fin de presentar una propuesta a la convocatoria ERA-NET EURONANOMED III (Proyectos europeos innovadores de investigación y desarrollo tecnológico en nanomedicina). El objetivo es diseñar, caracterizar, fabricar y comercializar un sensor avanzado para la detección in situ de la insuficiencia cardíaca. La fecha límite de la convocatoria es el 16 de enero de 2017.

Details

Tittle:
EURONANOMED: seeking SME in the field of cardiology, working on biomedicine and biosensing
Summary:
An international consortium including research groups on nanotechnology, materials, biomedicine and cardiology is seeking for an industrial partner for applying to the recently opened call entitled: EuroNanoMed III Joint Transnational Call for Proposals" for "European Innovative Research -Y- Technological Development Projects in Nanomedicine". The main target is the design, characterization, manufacturing and commercialization of an advanced sensor for the in situ detection of heart failure.
Description:
Heart failure (HF) is the leading cause of hospital admissions in the Medicare population, in addition to its high prevalence, hospitalization for decompensated heart failure is associated with extraordinarily high rates of morbidity and mortality. Moreover the diagnosis of heart failure can be difficult because some patients remain asymptomatic. In this context, the laboratory measurement of specific hormones produced by cardiac myocite in relation to increased wall stress and pressure as well as to other cardiac insult, has demonstrated an additive diagnostic power respect to traditional clinical approach: thus the blood assays of hormonal markers such as B-type natriuretic peptide (BNP), its precursor natriuretic (NT)-pro BNP and atrial natriuretic peptide (ANP) is universally accepted in the diagnostic algorithm and it is entered in the European and American guidelines for Heart failure management. However, serial dosages of the current hormones are limited to hospitalized patients and not available in the peripheral areas or in the general practice outpatient place.

In this project they aim to realize a non-invasive optoelectronic label free sensor based on biofunctionalized plasmonic nanoparticles with surface plasmon resonance (SPR) as read-out signal combined with microfluidic for BNP detection for assessing ventricular function and systemic congestion status which may be useful both for the diagnosis and monitoring of the response to medical therapy. An automatic device will be designed and validated to be used in clinic environment as diagnostic tool for BNP.

The combination of plasmonic nanoparticles with microfluidic architectures will allow increasing complex experiments and events to be monitored at the sensor/channel wall, such as the interaction of proteins and cells with immobilized biospecific markers or the growth of biofilm.
Their main goals are:
? synthesize and develop an efficient biosensor architecture for the BNP detection in blood plasma;
? maximize the chemical synthesis and biorecognition efficiency through nanoscale simulations and experiments, optimizing the sensor architecture;
? engineer and validation in vitro of the technological platform;
? clinic test and validate the assembled device in hospitalized patients for an immediate diagnosis of HF.
They are looking for SME would have interest and expertise on the cardiology field.
EOI Deadline: 15th January 2017
Deadline for call: 16th January 2017
Advantages and Innovations:
Main advantages over the existing diagnostic tools are envisaged for example a more sensibility, faster detection, and lower cost. We remark that existing methods for detecting BNP might take a few hours that are precious in diagnosing and treatment of HF. The biosensor will have a role in detecting, monitoring and allowing the prevention of episodes of acute HF in high-risk patients.
Stage of Development:
Concept stage

Partner sought

Partner Sought:
A SME working in biomedicine and biosensing with interest on expand its activity with nanotechnology-based products. Ideally, the SME would have interest and expertise on the cardiology field. The SME might assist on optimizing the production process at a large scale while complying with the safety and biocompatibility regulations. Additionally, the SME is expected to assist in the commercialization of the device.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No

Dissemination

Programme-call

Coordinator Required:
No
Deadline for Call:
16/01/2017
Project Duration:
144